CHRONO-MOBILIZE: Chronotherapy of G-CSF for CD34+ Mobilization in Healthy Donors

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-55
SponsorFirst Affiliated Hospital of Zhejiang University

About this trial

Healthy donors are commonly mobilized with granulocyte colony-stimulating factor (G-CSF) to collect peripheral blood stem cells for allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, the efficiency of mobilization varies among donors, and suboptimal mobilization may require additional collection procedures or rescue strategies.

This prospective, multicenter, randomized trial evaluates whether the timing of daily G-CSF administration (morning vs evening) affects the level of circulating CD34+ cells prior to apheresis in healthy donors. Participants will be randomly assigned to receive subcutaneous G-CSF 10 μg/kg once daily for 5 consecutive days either at 08:00 (±15 minutes) or at 20:00 (±15 minutes). The primary endpoint is the peripheral blood CD34+ cell count measured approximately 12 hours after the last G-CSF dose and within 60 minutes before the start of the first apheresis session. Secondary endpoints include collection efficiency and CD34+ yield metrics, the proportion of donors achieving the target CD34+ dose on the first collection day, the need for a second collection day, and donor safety outcomes.

The goal of the study is to identify a practical dosing schedule that may improve stem cell mobilization and streamline donor collection procedures.

Eligibility criteria

Qualifiers

Age 18-55 years

HLA matching appropriate for intended allo-HSCT recipient and meets donor medical evaluation criteria

Body weight ≥35 kg and adequate blood volume/BSA for apheresis

Karnofsky score ≥80

Disqualifiers

Prior/current hematologic or immune diseases (e.g., aplastic anemia, leukemia, lymphoma, autoimmune disease)

Significant cardiovascular/structural heart disease, uncontrolled hypertension, uncontrolled diabetes

Neurologic/psychiatric disorders affecting adherence

Sleep/circadian disorders; recent night shift or ≥3 time-zone travel

Trial design

Treatments tested in this trial

  • G-CSF (Granulocyte colony-stimulating factor)

Treatment groups

160 Participants
are divided into 2 treatment groups

Sponsors and collaborators

First Affiliated Hospital of Zhejiang University

Lead sponsor

The First Affiliated Hospital of Zhengzhou University

Collaborator

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Collaborator

Tongji Hospital

Collaborator

Ruijin Hospital

Collaborator